BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 16515596)

  • 21. Utility of thyroid transcription factor-1 and cytokeratin 7 and 20 immunostaining in the identification of origin in malignant effusions.
    Jang KY; Kang MJ; Lee DG; Chung MJ
    Anal Quant Cytol Histol; 2001 Dec; 23(6):400-4. PubMed ID: 11777274
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An outpatient intraperitoneal chemotherapy regimen for advanced ovarian cancer.
    Berry E; Matthews KS; Singh DK; Buttin BM; Lurain JR; Alvarez RD; Schink J
    Gynecol Oncol; 2009 Apr; 113(1):63-7. PubMed ID: 19201457
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The value of Cdx2 immunostaining in differentiating primary ovarian carcinomas from colonic carcinomas metastatic to the ovaries.
    Groisman GM; Meir A; Sabo E
    Int J Gynecol Pathol; 2004 Jan; 23(1):52-7. PubMed ID: 14668551
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Progression-free and overall survival of a modified outpatient regimen of primary intravenous/intraperitoneal paclitaxel and intraperitoneal cisplatin in ovarian, fallopian tube, and primary peritoneal cancer.
    Barlin JN; Dao F; Bou Zgheib N; Ferguson SE; Sabbatini PJ; Hensley ML; Bell-McGuinn KM; Konner J; Tew WP; Aghajanian C; Chi DS
    Gynecol Oncol; 2012 Jun; 125(3):621-4. PubMed ID: 22446622
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Patterns of recurrence in advanced epithelial ovarian, fallopian tube and peritoneal cancers treated with intraperitoneal chemotherapy.
    Esselen KM; Rodriguez N; Growdon W; Krasner C; Horowitz NS; Campos S
    Gynecol Oncol; 2012 Oct; 127(1):51-4. PubMed ID: 22659193
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intraperitoneal cisplatin and paclitaxel in ovarian cancer.
    Armstrong DK; Bundy B; Wenzel L; Huang HQ; Baergen R; Lele S; Copeland LJ; Walker JL; Burger RA;
    N Engl J Med; 2006 Jan; 354(1):34-43. PubMed ID: 16394300
    [TBL] [Abstract][Full Text] [Related]  

  • 27. SATB2 Expression Distinguishes Ovarian Metastases of Colorectal and Appendiceal Origin From Primary Ovarian Tumors of Mucinous or Endometrioid Type.
    Moh M; Krings G; Ates D; Aysal A; Kim GE; Rabban JT
    Am J Surg Pathol; 2016 Mar; 40(3):419-32. PubMed ID: 26551622
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Positive experience of intraperitoneal chemotherapy followed by intravenous chemotherapy in heavily pretreated patients with suboptimal residual ovarian cancer and primary peritoneal cancer.
    Nicoletto MO; Dalla Palma M; Donach ME; Gusella M; Cappetta A; Shams M; Marchet A; Nardin M; Pintacuda G; Di Maggio A; Marchesi M; Carli P; Fiduccia P; Artioli G; Nitti D
    Tumori; 2010; 96(6):918-25. PubMed ID: 21388052
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mucinous and nonmucinous bronchioloalveolar adenocarcinomas have distinct staining patterns with thyroid transcription factor and cytokeratin 20 antibodies.
    Goldstein NS; Thomas M
    Am J Clin Pathol; 2001 Sep; 116(3):319-25. PubMed ID: 11554157
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ovarian mucinous tumors associated with mature cystic teratomas: morphologic and immunohistochemical analysis identifies a subset of potential teratomatous origin that shares features of lower gastrointestinal tract mucinous tumors more commonly encountered as secondary tumors in the ovary.
    Vang R; Gown AM; Zhao C; Barry TS; Isacson C; Richardson MS; Ronnett BM
    Am J Surg Pathol; 2007 Jun; 31(6):854-69. PubMed ID: 17527072
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [A case of papillary adenocarcinoma of the ovary that responded favorably to irinotecan hydrochloride and cisplatin after the administration of paclitaxel and carboplatin].
    Shimoya K; Kunishige I; Okuno Y; Hayashi S; Komura H; Arimoto Y; Otsuki Y
    Gan To Kagaku Ryoho; 2001 Jun; 28(6):845-8. PubMed ID: 11432356
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Value of cytokeratin 7 and 20 for the diagnosis of cerebral metastases of adenocarcinoma: study of 78 cases].
    Fernandez C; Liprandi A; Bouvier-Labit C; Figarella-Branger D
    Ann Pathol; 2001 Apr; 21(2):129-35. PubMed ID: 11373582
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term survival after incomplete resection of immunohistochemically diagnosed T0N1 lung cancer: report of a case.
    Izumi Y; Mukai M; Kikuchi K; Kobayashi K
    Surg Today; 2006; 36(3):270-3. PubMed ID: 16493539
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cytokeratins 7 and 20 in primary and secondary mucinous tumors of the ovary: analysis of coordinate immunohistochemical expression profiles and staining distribution in 179 cases.
    Vang R; Gown AM; Barry TS; Wheeler DT; Yemelyanova A; Seidman JD; Ronnett BM
    Am J Surg Pathol; 2006 Sep; 30(9):1130-9. PubMed ID: 16931958
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [A case of primary breast cancer responding to pre-operative chemotherapy with the combination of paclitaxel and carboplatin for ovarian cancer].
    Kitagawa D; Nako Y; Honda Y; Shigekawa T; Horiguchi K; Aruga T; Yamashita T; Kuroi K
    Gan To Kagaku Ryoho; 2012 Jun; 39(6):1013-6. PubMed ID: 22705705
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognosis of stage III or IV primary peritoneal serous papillary carcinoma.
    Dubernard G; Morice P; Rey A; Camatte S; Fourchotte V; Thoury A; Pomel C; Pautier P; Lhommé C; Duvillard P; Castaigne D
    Eur J Surg Oncol; 2004 Nov; 30(9):976-81. PubMed ID: 15498644
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vascular endothelial growth factor (VEGF) expression in primary tumors and peritoneal metastases from patients with advanced ovarian carcinoma.
    Gadducci A; Viacava P; Cosio S; Cecchetti D; Fanelli G; Fanucchi A; Teti G; Genazzani AR
    Anticancer Res; 2003; 23(3C):3001-8. PubMed ID: 12926153
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term survival after paclitaxel plus platinum-based combination chemotherapy for extraovarian peritoneal serous papillary carcinoma: is it different from that for ovarian serous papillary cancer?
    Ayhan A; Taskiran C; Yigit-Celik N; Bozdag G; Gultekin M; Usubutun A; Guler N; Yuce K
    Int J Gynecol Cancer; 2006; 16(2):484-9. PubMed ID: 16681715
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combination chemotherapy with paclitaxel and intraperitoneal cisplatin for ovarian cancer with disseminated lesions in the peritoneum and the diaphragm.
    Terauchi F; Moritake T; Yamamoto Y; Ogura H
    Int J Clin Oncol; 2002 Dec; 7(6):356-60. PubMed ID: 12494251
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Improved tolerance of primary chemotherapy with reduced-dose carboplatin and paclitaxel in elderly ovarian cancer patients.
    Fader AN; von Gruenigen V; Gibbons H; Abushahin F; Starks D; Markman M; Belinson J; Rose P
    Gynecol Oncol; 2008 Apr; 109(1):33-8. PubMed ID: 18261784
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.